Previous 10 | Next 10 |
The most heavily shorted names have been rallying off their lows in the past several days. On a relative basis, the 100 most heavily shorted stocks versus the Russell 3,000 have broken out of the downtrend that has been in place since the height of the meme stock mania in January 2021...
MORRISTOWN, N.J., June 21, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that multiple abstracts highli...
The commercial-stage biotech Intercept Pharmaceuticals (NASDAQ:ICPT) announced on Monday that the FDA has delayed the pre-submission meeting regarding its marketing application for the liver disease therapy Ocaliva in nonalcoholic steatohepatitis (NASH). The meeting previously scheduled for J...
MORRISTOWN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat non-viral liver diseases, today announced an update on the timing of its pre-submiss...
Commercial-stage biotech Intercept Pharmaceuticals (NASDAQ:ICPT) announced a mixed performance for its liver disease therapy Ocaliva (obeticholic acid or OCA) from two studies on Friday to support the post-marketing regulatory requirements of the drug. Ocaliva, a farnesoid X receptor (FXR) ag...
COBALT study in advanced PBC, previously terminated early due to feasibility challenges, did not demonstrate a statistically significant difference in clinical endpoints between Ocaliva ® and placebo HEROES-US real-world analysis demonstrated statistically signi...
Palm Beach, FL – May 24, 2022 – FinancialNewsMedia.com News Commentary – The Global psychedelic drugs market has been steadily rising for the past few years and is projected to continue at a faster pace in years to come. The rising prevalence of mental depre...
Final data from the phase 3 REGENERATE study, using Ocaliva for the treatment of patients with NASH fibrosis, is expected any day now. If all goes well with clinical data, Intercept expects a pre-submission meeting with the FDA in June of 2022. Results from the phase 3 REVERSE stu...
S3 Partners ran an intriguing screen to find the most crowded shorts in the market. In looking at the stocks under attack, the firm said a short can be considered to be "crowded" if there are large amount of dollars at risk on the short side, a large proportion of a stock's float is being sho...
Intercept Pharma (NASDAQ:ICPT) said on Wednesday the first patient had been dosed in a Phase 2 study evaluating a fixed-dose combination of its drug, obeticholic acid with bezafibrate for the treatment of patients with primary biliary cholangitis, a rare liver condition. The company...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...